Diagnostics & Research Industry | Healthcare Sector | Mr. Jacob Thaysen Ph.D. CEO | B3 Exchange | US4523271090 ISIN |
US Country | 10,590 Employees | - Last Dividend | - Last Split | 28 Jul 2000 IPO Date |
Illumina, Inc. is a leader in the development and manufacturing of sequencing- and array-based solutions designed for genetic and genomic analysis. With operations spanning the United States, Singapore, the United Kingdom, and other international markets, Illumina serves a diverse set of customers, including genomic research centers, academic institutions, government laboratories, hospitals, as well as players in the pharmaceutical and biotechnology industries, commercial molecular diagnostic laboratories, and consumer genomics companies. The company's product offerings are critical in facilitating comprehensive genomic studies, contributing significantly to advancements in genetic health and personalized medicine. Founded in 1998, Illumina has its headquarters in San Diego, California, and operates through two main segments: Core Illumina and GRAIL, the latter focusing on the development of Galleri, a groundbreaking multi-cancer early detection test. Illumina's commitment to innovation is evident in its continuous efforts to develop new solutions aimed at accelerating cancer diagnoses and enhancing blood-based detection methods for minimal residual disease, among other post-diagnostic applications.
Illumina's portfolio encompasses a comprehensive range of sequencing and array-based instruments, consumables, and services tailored for genomic analysis. These include:
All products and services offered by Illumina are marketed and distributed directly to customers, as well as through life-science distributors, ensuring a wide-reaching impact on the field of genomics.